Filing Flows › Comparisons › ZNTL vs LFCR
Zentalis Pharmaceuticals vs Lifecore Biomedical: ZNTL and LFCR compared
Zentalis Pharmaceuticals is the larger company: $26.9M of revenue in its latest quarter (Q4 2024) against $25.3M for Lifecore Biomedical (Q1 FY27). Lifecore Biomedical is more profitable, with an operating margin of -3.5% against -185.6%.
Where the money goes: ZNTL and LFCR
Zentalis Pharmaceuticals (ZNTL) · Q4 2024
Zentalis Pharmaceuticals, Q4 2024: revenue $26.9M, operating margin -185.6%, net loss $47.5M, operating cash flow −$39.7M. The chart follows the revenue to costs, profit and cash.
Lifecore Biomedical (LFCR) · Q1 FY27
Lifecore Biomedical, Q1 FY27: revenue $25.3M (-19% year over year), operating margin -3.5%, net loss $40.1M, operating cash flow $6.9M. The chart follows the revenue to costs, profit and cash.
| Zentalis Pharmaceuticals (ZNTL) | Lifecore Biomedical (LFCR) | |
|---|---|---|
| Latest quarter | Q4 2024 | Q1 FY27 |
| Revenue | $26.9M | $25.3M |
| Revenue growth, Y/Y | — | -19% |
| Operating margin | -185.6% | -3.5% |
| Net earnings | −$47.5M | −$40.1M |
| Net margin | -176.7% | -158.3% |
| Operating cash flow | −$39.7M | $6.9M |
| Free cash flow | — | $6.0M |
Where the revenue comes from
Lifecore Biomedical
- CDMO: $17.8M (70%)
- HA manufacturing: $7.5M (30%)
Questions
Which is bigger, Zentalis Pharmaceuticals or Lifecore Biomedical?
Zentalis Pharmaceuticals is the larger company: $26.9M of revenue in its latest quarter (Q4 2024) against $25.3M for Lifecore Biomedical (Q1 FY27).
Is Zentalis Pharmaceuticals or Lifecore Biomedical growing faster?
Lifecore Biomedical is more profitable, with an operating margin of -3.5% against -185.6%.
More: Zentalis Pharmaceuticals earnings · how Zentalis Pharmaceuticals makes money · Lifecore Biomedical earnings · how Lifecore Biomedical makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 26, 2025; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.